Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

15.14USD
10:41am EDT
Change (% chg)

$0.60 (+4.13%)
Prev Close
$14.54
Open
$15.76
Day's High
$15.76
Day's Low
$14.95
Volume
147,947
Avg. Vol
129,715
52-wk High
$16.40
52-wk Low
$7.20

Latest Key Developments (Source: Significant Developments)

Omeros reports more positive data in OMS721 phase 2 trial in renal diseases
7:00am EDT 

Omeros Corp : Omeros reports more positive data in OMS721 phase 2 trial in renal diseases . Phase 3 program slated for this year . Consistent with all other OMS721 clinical trials, no significant safety concerns have been observed . Preparing breakthrough application and phase 3 protocol for discussion with FDA; phase 3 trial in IGAN expected to begin this year .New data corroborate and expand on trial results reported in Q4 of 2016.  Full Article

Omeros to present results from dose-ranging stage of OMS721 Clinical Trial
Monday, 27 Mar 2017 07:00am EDT 

Omeros Corp : Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology . Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology . Omeros corp - mean change from baseline in platelet count was statistically significant as measured by area under curve .Omeros- renal replacement therapy able to be discontinued in 1 patient during oms721 treatment, renal function remained stable following completion of treatment.  Full Article

Omeros reports additional positive results from OMS721 Phase 2 trial
Wednesday, 1 Mar 2017 07:00am EST 

Omeros Corp : Omeros reports additional positive results from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy . Omeros Corp - total of ten serious adverse events have been reported, none considered related to OMS721 treatment . Omeros Corp - two patients died of progression of cancer after less than three weeks of OMS721 treatment . Omeros Corp - one patient died of graft failure after completing study and positively responding to oms721 .Omeros Corp - none of these deaths was considered by investigators to be related to OMS721 treatment..  Full Article

Omeros announces pricing of public offering of common stock
Thursday, 11 Aug 2016 10:49am EDT 

Omeros Corp : Omeros announces pricing of public offering of common stock .Pricing of a $40 million underwritten public offering of its common stock at a price to public of $11.50 per share.  Full Article

Omeros announces public offering of common stock
Wednesday, 10 Aug 2016 04:01pm EDT 

Omeros Corp : Omeros announces public offering of common stock . Intends to use net proceeds for funding research and development expenses for its clinical OMS721 program and clinical trials .Says announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co..  Full Article

Omeros confirms late-stage development plan for OMS721 with EMA
Thursday, 28 Jul 2016 09:27am EDT 

Omeros Corp : Omeros corporation confirms oms721 phase 3 development plan with european medicines agency . Initiation of enrollment in ahus phase 3 clinical trial is planned for late this year . Omeros plans to commercialize oms721 initially for administration as a subcutaneous injection .One single-arm, open-label phase 3 pivotal trial planned to support approval in both europe and u.s..  Full Article

Omeros enters debt financing transaction for $20 mln in additional funds
Tuesday, 17 May 2016 07:00am EDT 

Omeros Corp : Entered into an amendment to its existing credit facility to provide company with an additional $20 million in unrestricted cash . Will issue warrants to lenders, exercisable for 7 years for up to 100,602 shares of common stock at an exercise price per share of $9.94 . Expects funding will occur on may 18, 2016. .Omeros announces debt financing transaction for $20 million in additional funds.  Full Article

Omeros Corporation reports Q1 loss per share $0.54
Tuesday, 10 May 2016 07:29am EDT 

Omeros Corp : Omeros corporation reports first quarter 2016 financial results . Q1 loss per share $0.54 . Q1 revenue $7.4 million versus I/B/E/S view $8.8 million . Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S ."continue to expect that we will reach cash-flow positive status later this year, fully funding our pipeline".  Full Article

Omeros Corp announces exclusive Middle East distribution agreement
Tuesday, 10 May 2016 07:00am EDT 

Omeros Corporation : Omeros Corporation announces exclusive middle east distribution agreement for omidria .Distribution agreement for sale of omidria in Saudi Arabia, UAE and other countries in Middle East with Itrom Trading Drug Store.  Full Article

Omeros Corp Files Infringement Suits Against Par
Thursday, 3 Sep 2015 09:15am EDT 

Omeros Corp:Filed patent infringement lawsuits against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC, (collectively "Par") in the U.S. District Court for the District of New Jersey and in U.S. District Court for the District of Delaware.lawsuits were filed under the Hatch-Waxman Act for Par's infringement of three Omeros patents, U.S. Patent Nos. 8,173,707, 8,586,633 and 9,066,856.which relate to Omeros' drug Omidria(phenylephrine and ketorolac injection) 1%/0.3% and which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book, published by FDA.Under the Hatch-Waxman Act, Omeros was permitted to file suit within 45 days from its receipt of Par's notice and thereby trigger a 30-month stay of the FDA's approval of Par's ANDA.stay is expected to remain in effect until March 2018. Omeros has reviewed Par's Paragraph IV assertions and believes they do not have merit\.Omeros has sought access to Par's ANDA, which Par is legally required to provide under reasonable terms, but to date Par has not provided this access.Omeros will obtain access to Par's ANDA and will vigorously prosecute its infringement claims against Par.  Full Article

More From Around the Web

BRIEF-Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

* Omeros reports more positive data in OMS721 phase 2 trial in renal diseases